Compare GAB & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAB | NVCR |
|---|---|---|
| Founded | 1986 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | GAB | NVCR |
|---|---|---|
| Price | $5.42 | $11.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $25.57 |
| AVG Volume (30 Days) | 919.7K | ★ 1.7M |
| Earning Date | 01-01-0001 | 10-29-2026 |
| Dividend Yield | ★ 10.91% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $12.95 |
| Revenue Next Year | N/A | $9.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $5.09 | $9.82 |
| 52 Week High | $6.37 | $21.45 |
| Indicator | GAB | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.04 | 32.38 |
| Support Level | $5.28 | $11.73 |
| Resistance Level | $5.72 | $18.43 |
| Average True Range (ATR) | 0.08 | 0.86 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 95.65 | 8.80 |
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.